Intermittent Claudication Market Report 2026

Intermittent Claudication Market Overview

• Intermittent Claudication market size has reached to $13.51 billion in 2025 • Expected to grow to $17.98 billion in 2030 at a compound annual growth rate (CAGR) of 5.9% • Growth Driver: Rising Cases Of Peripheral Artery Disease Fueling The Growth Of The Market Due To Increasing Prevalence And Risk Factors • Market Trend: Integration of Advanced Endovascular Innovations in Disease Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Intermittent Claudication Market?

Intermittent claudication is a condition characterized by muscle pain, cramping, or discomfort in the legs that occurs during physical activity, such as walking, and is relieved by rest. It is typically caused by peripheral artery disease (PAD), which results from narrowed or blocked arteries reducing blood flow to the muscles. The pain is often due to insufficient oxygen supply (ischemia) to the affected muscles. The main types of intermittent claudication are medication therapies and revascularization procedures. Medication therapies involve the use of drugs to alleviate symptoms, enhance blood flow, reduce pain, and prevent complications arising from poor circulation. These therapies are administered through various routes, including parenteral, oral, and others, and span across diverse settings such as hospitals, clinics, home healthcare, and others. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Intermittent Claudication Market Growth Forecast?

The intermittent claudication market size is expected to see strong growth in the next few years. It will grow to $17.98 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing awareness of peripheral artery disease symptoms, growing demand for minimally invasive vascular treatments, advancements in pharmacological therapies, rising adoption of home-based disease management, improved screening and diagnostic programs. Major trends in the forecast period include increasing focus on early diagnosis of peripheral artery disease, rising adoption of combination drug therapies, growing preference for minimally invasive revascularization procedures, expansion of supervised exercise therapy programs, improved patient awareness and disease management.

Global Intermittent Claudication Market Segmentation

1) By Type: Medication Therapies, Revascularization 2) By Route Of Administration: Parenteral Route, Oral Route, Other Routes Of Administration 3) By Application: Hospitals, Clinics, Home Healthcare, Other Applications 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Medication Therapies: Antiplatelet Agents, Vasodilators, Phosphodiesterase Inhibitors, Cilostazol, Pentoxifylline 2) By Revascularization: Angioplasty, Stenting, Bypass Surgery, Endarterectomy

What Is The Driver Of The Intermittent Claudication Market?

The increasing cases of peripheral artery disease (PAD) are expected to fuel the growth of the intermittent claudication market going forward. Peripheral artery disease refers to a circulatory condition where narrowed arteries reduce blood flow to limbs, causing pain, numbness, and complications. Increasing cases of peripheral artery disease are attributed to factors such as an aging population, diabetes, smoking, hypertension, obesity, and sedentary lifestyles. Peripheral artery disease (PAD) causes intermittent claudication by reducing blood flow to leg muscles during exercise, leading to pain and cramping due to oxygen deprivation. For instance, in June 2023, according to the American Heart Association Journals, a US-based peer-reviewed open-access scientific journal, peripheral artery disease (PAD) affects 7-12 million in the U.S. and 200 million globally. Therefore, the increasing cases of peripheral artery disease (PAD) are driving the growth of the intermittent claudication industry.

Key Players In The Global Intermittent Claudication Market

Major companies operating in the intermittent claudication market are Pfizer Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories, Alkem Laboratories, Aastrid Life Sciences Pvt. Ltd., Manus Aktteva Biopharma LLP, Enomark Pharma.

Global Intermittent Claudication Market Trends and Insights

Major companies operating in the Intermittent Claudication market are focusing on incorporating minimally invasive endovascular innovations such as percutaneous bypass systems to enhance treatment efficiency, procedural success, and patient outcomes. Percutaneous bypass systems are advanced vascular technologies that create an endovascular bypass pathway using specialized stent grafts and catheters, enabling capabilities such as restoring blood flow across long arterial blockages, reducing reliance on open surgical bypass, and supporting faster patient recovery. For instance, in June 2023, Endologix LLC, a US-based medical device company specializing in therapies for vascular disease, received FDA approval for its DETOUR System, a minimally invasive percutaneous bypass solution designed to treat long, complex superficial femoropopliteal lesions in patients with peripheral artery disease (PAD). The system features the TORUS stent graft platform, a novel endovascular bypass technique, and the capability to address long-segment occlusions, enabling effective treatment of challenging femoropopliteal blockages. The DETOUR System enhances blood flow restoration, reduces procedural morbidity, and expands treatment options for patients with symptomatic PAD and intermittent claudication.

What Are Latest Mergers And Acquisitions In The Intermittent Claudication Market?

In April 2023, Abbott Laboratories, a US-based healthcare company, acquired Cardiovascular Systems Inc. for $890 million. This acquisition aims to broaden Abbott’s vascular device portfolio by incorporating Cardiovascular Systems Inc.'s cutting-edge technologies for treating peripheral and coronary artery disease. The move strengthens Abbott’s position in the cardiovascular market and enhances patient care through advanced minimally invasive solutions. Cardiovascular Systems Inc. is a US-based medical device company that specializes in providing innovative solutions for treating peripheral artery disease (PAD), including intermittent claudication.

Regional Outlook

North America was the largest region in the intermittent claudication market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Intermittent Claudication Market?

The intermittent claudication market includes revenues earned by entities by providing services such as non-invasive tests, angioplasty, stent placement, supervised exercise therapy, and nutritional counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The intermittent claudication market also consists of sales of antiplatelet agents, statins, vasodilators, and special socks or stockings. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Intermittent Claudication Market Report 2026?

The intermittent claudication market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the intermittent claudication industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.